Literature DB >> 2276389

Effect of omeprazole and cimetidine on plasma diazepam levels.

T Andersson1, K Andrén, C Cederberg, G Edvardsson, A Heggelund, P Lundborg.   

Abstract

The effects of steady state dosing with omeprazole and cimetidine on plasma diazepam levels have been studied in 12 healthy males. Single doses of diazepam (0.1 mg.kg-1 i.v.) were administered after one week of treatment with omeprazole 20 mg once daily, cimetidine 400 mg b.d. or placebo, and the treatment was continued for a further 5 days. Blood was collected for 120 h after the dose of diazepam for the measurement of diazepam and its major metabolite desmethyl diazepam. The mean clearance of diazepam was decreased by 27% and 38% and its half-life was increased by 36% and 39% after omeprazole and cimetidine, respectively. Neither drug had any apparent effect on the volume of distribution of diazepam. Desmethyldiazepam appeared more slowly after both omeprazole and cimetidine. It is concluded that the decrease in diazepam clearance was associated with inhibition of hepatic metabolism both by omeprazole and cimetidine. However, since diazepam has a wide therapeutic range, it is unlikely that concomitant treatment with therapeutically recommended doses of either omeprazole or cimetidine will result in a clinically significant interaction with diazepam.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276389     DOI: 10.1007/bf02657057

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  Drug interactions involving cimetidine--mechanisms, documentation, implications.

Authors:  W Greene
Journal:  Q Rev Drug Metab Drug Interact       Date:  1984

Review 2.  Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo.

Authors:  R Gugler; J C Jensen
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

3.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

4.  The relationship between the binding of 2-n-alkylbenzimidazoles to rat hepatic microsomal cytochrome P-450 and the inhibition of monooxygenation.

Authors:  M Dickins; J W Bridges
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

5.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

6.  Clinical importance of the interaction of diazepam and cimetidine.

Authors:  D J Greenblatt; D R Abernethy; D S Morse; J S Harmatz; R I Shader
Journal:  N Engl J Med       Date:  1984-06-21       Impact factor: 91.245

7.  Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

Authors:  R Larsson; P Erlanson; G Bodemar; B Norlander; L Fransson; L Strouth
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Omeprazole: effects on oxidative drug metabolism.

Authors:  D A Henry; K W Somerville; G Kitchingman; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

9.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

10.  Propranolol steady-state pharmacokinetics are unaltered by omeprazole.

Authors:  D Henry; P Brent; I Whyte; G Mihaly; S Devenish-Meares
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more
  29 in total

1.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Theophylline steady state pharmacokinetics is not altered by omeprazole.

Authors:  A M Taburet; J Geneve; M Bocquentin; G Simoneau; C Caulin; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

5.  Prescription of proton pump inhibitors in older adults with complex polytherapy.

Authors:  Clara Cena; Sara Traina; Beatrice Parola; Mario Bo; Riccardo Fagiano; Carlotta Siviero
Journal:  Eur J Hosp Pharm       Date:  2019-03-16

Review 6.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 9.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.